Skip to main content
SpringerLink
Log in

Introduction to Non-Hodgkin’s Lymphoma

  • Chapter
  • First Online:
PET/CT in Non-Hodgkin Lymphoma

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

  • 494 Accesses

Abstract

The Non-Hodgkin’s Lymphoma (NHL) includes a wide-spectrum of disorders with varied clinical and biological behavior. This chapter focuses on the spectrum of clinical presentation of NHL and diagnostics with particular emphasis on the common NHLs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lymphoma—Non-Hodgkin: Statistics|Cancer.Net. https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/statistics. Accessed 22 Nov 2020.

  2. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    Article  CAS  Google Scholar 

  3. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.

    Article  CAS  Google Scholar 

  4. Safar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol. 2012;30:184–90.

    Article  CAS  Google Scholar 

  5. Pregno P, Chiappella A, Bellò M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066–73.

    Article  CAS  Google Scholar 

  6. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–67.

    Article  Google Scholar 

  7. Fisher RI. The New England Journal of Medicine. No other uses without permission. Copyright © 1993 Massachusetts Medical Society. All rights reserved. N Engl J Med. 1993;29:1230–5.

    Google Scholar 

  8. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–80.

    Article  CAS  Google Scholar 

  9. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.

    Article  CAS  Google Scholar 

  10. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.

    Article  Google Scholar 

  11. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.

    Article  CAS  Google Scholar 

  12. Junlén HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia. 2015;29:668–76.

    Article  Google Scholar 

  13. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting—Airlie house, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.

    Article  CAS  Google Scholar 

  14. Nguyen LN, Ha CS, Hess M, Romaguera JE, Manning JT, Cabanillas F, Cox JD. The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys. 2000;47:1281–5.

    Article  CAS  Google Scholar 

  15. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. T-cell/Histiocyte–rich large B-cell lymphoma: a distinct Clinicopathologic entity. J Clin Oncol. 2002;20:1269–77.

    CAS  PubMed  Google Scholar 

  16. Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med. 2008;132(11):1830–4. https://doi.org/10.1043/1543-2165-132.11.1830.

    Article  PubMed  Google Scholar 

  17. Ferreri AJM, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–72.

    Article  Google Scholar 

  18. Novak U, Basso K, Pasqualucci L, Dalla-Favera R, Bhagat G. Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells. Br J Haematol. 2011;155:362–5.

    Article  CAS  Google Scholar 

  19. Sagaert X, De Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: where do we stand? Leukemia. 2007;21:389–96.

    Article  CAS  Google Scholar 

Download references

Acknowledgement Dr. Krishna Prasad for simplifying the concepts of lymphoma.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India

    Hasmukh Jain, Abhinav Zawar & Jayashree Thorat

Authors
  1. Hasmukh Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abhinav Zawar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jayashree Thorat
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India

    Archi Agrawal

  2. Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India

    Venkatesh Rangarajan

  3. Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India

    Ameya D. Puranik

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jain, H., Zawar, A., Thorat, J. (2021). Introduction to Non-Hodgkin’s Lymphoma. In: Agrawal, A., Rangarajan, V., Puranik, A.D. (eds) PET/CT in Non-Hodgkin Lymphoma . Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-030-79007-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-79007-3_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-79006-6

  • Online ISBN: 978-3-030-79007-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation